SOUTH SAN FRANCISCO, Calif., Nov. 21, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, reported that it received a letter, dated November 19, 2008, from the Listing Qualifications Department of The NASDAQ Stock Market notifying the Company that it does not comply with the $2.5 million minimum stockholders’ equity requirement for continued listing on The NASDAQ Capital Market set forth in NASDAQ Marketplace Rule 4310(c)(3). NASDAQ’s determination was based on a review of the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2008.
